Abstract
Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.
Original language | English (US) |
---|---|
Pages (from-to) | 1008-1013 |
Number of pages | 6 |
Journal | Advanced Healthcare Materials |
Volume | 5 |
Issue number | 9 |
DOIs | |
State | Published - May 11 2016 |
Keywords
- Fibroblast growth factor-2 (FGF-2)
- Ischemia
- Peripheral vascular diseases
- Syndecan-4
- Therapeutic angiogenesis
ASJC Scopus subject areas
- Biomaterials
- Biomedical Engineering
- Pharmaceutical Science